Background: Metabolic syndrome (MetS) is a growing worldwide health problem. However, there is yet no effective therapy for MetS. The present work investigated the effect of liraglutide, a synthetic glucagon-like peptide-1 and vitamin E on fructose-induced MetS in rats. Summary: Liraglutide (0.3 mg/kg/day) and vitamin E (100 mg/kg/day) were administered either alone or in combination with high fructose-fed male rats for 6 weeks. Fructose-fed rats developed metabolic disorders assessed by visceral fat index, serum glucose, serum insulin, homeostasis model assessment-insulin resistance and serum lipids profile and hepatic disorders assessed by liver index, serum alanine aminotransferase and aspartate aminotransferase and steatohepatitis in histopathology. This study showed that liraglutide, vitamin E and their combination significantly ameliorated the fructose-induced metabolic and hepatic disorders. Key Messages: These results indicate a potential therapeutic benefit of liraglutide and vitamin E combination in prevention of MetS. Their protective effects might rely on their antioxidant effects as well as on the inhibition of tumor necrosis factor-α.

1.
van Kuijk JP, Flu WJ, Chonchol M, Bax JJ, Verhagen HJ, Poldermans D: Metabolic syndrome is an independent predictor of cardiovascular events in high-risk patients with occlusive and aneurysmatic peripheral arterial disease. Atherosclerosis 2010;210:596-601.
2.
Van Buul VJ, Tappy L, Brouns FJ: Misconceptions about fructose-containing sugars and their role in the obesity epidemic. Nutr Res Rev 2014;27:119-130.
3.
Panchal SK, Brown L: Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011;2011:351982.
4.
Paneni F, Costantino S, Cosentino F: Role of oxidative stress in endothelial insulin resistance. World J Diabetes 2015;6:326-332.
5.
Neumiller JJ, Sonnett TE, Wood LD, Setter SM, Campbell RK: Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2010;3:215-226.
6.
Wajcberg E, Amarah A: Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther 2010;4:279-290.
7.
Traber MG, Stevens JF: Vitamins C and E: beneficial effects from a mechanistic perspective. Free Radic Biol Med 2011;51:1000-1013.
8.
Ibrahim MA, Kelleni M, Geddawy A: Nonalcoholic fatty liver disease: current and potential therapies. Life Sci 2013;92:114-118.
9.
Kasprzak A, Zabel M, Biczysko W, Wysocki J, Adamek A, Spachacz R, Surdyk-Zasada J: Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J Histochem Cytochem 2004;52:29-38.
10.
Baky N, Faddah LM, Al-Rasheed NM, Al-Rasheed NM, Fatani AJ: Induction of inflammation, DNA damage and apoptosis in rat heart after oral exposure to zinc oxide nanoparticles and the cardioprotective role of α-lipoic acid and vitamin E. J Cardiovasc Risk 2013;10:121-128.
11.
Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ: Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 2011;19:1342-1349.
12.
Hansen PA, Han DH, Nolte LA, Chen M, Holloszy JO: DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol 1997;273(5 pt 2):1704-1708.
13.
Whiting PH, Thomson KJ, Saunders NJ, Simpson JG: The effects of cyclosporin A on glucose homeostasis and the kidney in the normal rat. J Exp Pathol (Oxford) 1990;71:245-255.
14.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15.
Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-310.
16.
Nishikimi M, Appaji N, Yagi K: The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem Biophys Res Commun 1972;46:849-854.
17.
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
18.
Ibrahim M, Farghaly E, Gomaa W, Kelleni M, Abdelrahman AM: Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur J Pharmacol 2011;659:289-295.
19.
de Castro UG, dos Santos RA, Silva ME, de Lima WG, Campagnole-Santos MJ, Alzamora AC: Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats. Lipids Health Dis 2013;12:136.
20.
Basciano H, Federico L, Adeli K: Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005;2:5.
21.
Rayssiguier Y, Gueux E, Nowacki W, Rock E, Mazur A: High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation. Magnes Res 2006;19:237-243.
22.
Wang JK, Feng ZW, Li YC, Li QY, Tao XY: Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2012;27:670-676.
23.
Hoang V, Bi J, Mohankumar SM, Vyas AK: Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome. PLoS One 2015;10:0126119.
24.
Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616.
25.
Russo GT, Labate AM, Giandalia A, Romeo EL, Villari P, Alibrandi A, Perdichizzi G, Cucinotta D: Twelve-month treatment with liraglutide ameliorates visceral adiposity index and common cardiovascular risk factors in type 2 diabetes outpatients. J Endocrinol Invest 2015;38:81-89.
26.
Fransson L, Dos Santos C, Wolbert P, Sjöholm A, Rafacho A, Ortsäater H: Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome. Diabetol Metab Syndr 2014;6:3.
27.
Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: the extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009;94:1843-1852.
28.
Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K: The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal 2012;2012:496453.
29.
Vinodraj K, Nagendra Nayak IM, Rao JV, Mathai P, Chandralekha N, Nitasha B, Rajesh D, Chethan TK: Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats. Indian J Pharmacol 2015;47:181-184.
30.
Morino K, Petersen KF, Shulman GI: Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006;55(suppl 2):S9-S15.
31.
Li L, Miao Z, Liu R, Yang M, Liu H, Yang G: Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 2011;17:1168-1178.
32.
Gao H, Xu L, Li D, Guang L, Deng W: Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease. Nan Fang Yi Ke Da Xue Xue Bao 2013;33:1661-1664.
33.
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679-690.
34.
Ihara Y, Yamada Y, Toyokuni S, Miyawaki K, Ban N, Adachi T, Kuroe A, Iwakura T, Kubota A, Hiai H, Seino Y: Antioxidant alpha-tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes. FEBS Lett 2000;473:24-26.
35.
Ji HF, Sun Y, Shen L: Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis. Nutrition 2014;30:986-991.
36.
Xu G, Shneider BL, Shefer S, Nguyen LB, Batta AK, Tint GS, et al: Ileal bile acid transport regulates bile acid pool, synthesis, and plasma cholesterol levels differently in cholesterol-fed rats and rabbits. J Lipid Res 2000;41:298-304.
37.
Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, Zhao SX, Zhao JM, Yu J: Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009;44:1121-1131.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.